Skip to main content
SpringerLink
Log in

Factors predisposing cancer patients to infection

  • Chapter
Infectious Complications of Cancer

Part of the book series: Cancer Treatment and Research ((CTAR,volume 79))

Abstract

As a consequence of major advances in medicine in the last few decades, patients with illnesses previously considered untreatable may now receive appropriate treatment and survive. Unfortunately, this progress has not been obtained without a price. The increased aggressiveness and invasiveness of the various medical procedures characteristic of modern medicine creates numerous disruptions of immunological protection systems, with a consequent increased patient susceptibility to developing opportunistic infections. The net result is that patients with a controlled underlying condition may succumb to bacterial, fungal, viral, or protozoal infections. Preventing and treating these infections represent an exciting challenge for the infectious disease physician, because in some instances an appropriate antimicrobial intervention may signify the difference between death and life for the patient. This is particularly true in the field of cancer, in which managing infectious complications has become one of the major goals of treatment. Until the advent of the acquired immunodeficiency syndrome (AIDS), much of what had been written about infections in immunocompromised hosts actually stemmed from studies and experience obtained with cancer patients. These studies represented the mainstay for our understanding of the natural history of infectious complications in patients affected with AIDS. It has not been by chance that infectious disease physicians operating in cancer centers were among the first to report opportunistic infections in AIDS [1–3].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 259.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Armstrong D, Gold JW, Dryjanski J, et al. 1985. Treatment of Infections in patients with the acquired immunodeficiency syndrome. Ann Intern Med 103:783–743.

    Google Scholar 

  2. Hughes WT. 1987. Pneumocystis Carinii. Boca Raton, FL: CRC Press.

    Google Scholar 

  3. Pizzo PA. 1990. Pediatric AIDS: Problems within problems. J Infect Dis 161:316–325.

    PubMed  CAS  Google Scholar 

  4. Hersh EM, Bodey GP, Nies BA. 1965. Cause of death in acute leukemia. JAMA 193:105–109.

    PubMed  CAS  Google Scholar 

  5. Hughes WT. 1971. Fatal infections in childhood leukemia. Am J Dis Child 122:283–287.

    PubMed  CAS  Google Scholar 

  6. Levine AS, Schimpff SC, Graw RG Jr, et al. 1974. Hematologic malignancies and other marrow failure states: Progress in the management of complicating infections. Semin Hematol 11:141–202.

    PubMed  CAS  Google Scholar 

  7. Chang H-Y, Rodriguez V, Narboni G, et al. 1976. Causes of death in adults with acute leukemia. Medicine (Baltimore) 55:259–268.

    CAS  Google Scholar 

  8. Feld R, Bodey GP. 1977. Infections in patients with malignant lymphoma treated with combination chemotherapy. Cancer 39:1018–1025.

    PubMed  CAS  Google Scholar 

  9. Pizzo PA, Meyers, J. 1989. Infections in the cancer patient. In: De Vita VT, Hellma S, Rosenbreg SA, eds Principles and Practice of Oncology. Philadelphia: JB Lippincott, pp 2088–2133.

    Google Scholar 

  10. Crawford J, Ozer H, Stoller R, et al. 1991. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325:164–170.

    PubMed  CAS  Google Scholar 

  11. Trillet-Lenoir V, Green J, Manegold C, et al. 1993. Recombinant granulocyte colony-stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 29A:319–332.

    PubMed  CAS  Google Scholar 

  12. Morittu L, Earl HM, Souhami RL, et al. 1989. Patients at risk of chemotherapy-associated toxicity in small cell lung cancer. Br J Cancer 59:801–804.

    PubMed  CAS  Google Scholar 

  13. Meyers J, Thomas ED. 1988. Infection complicating bone marrow transplantation. In: Rubin RH, Young LS, eds Clinical Approach to Infection in the Compromised Patient. New York: Plenum, pp 525–556.

    Google Scholar 

  14. Viscoli C, Boni L, Etzioni R, et al. 1994. Infections in recipients of bone marrow transplants from unrelated donors. Program and Abstract of the 8th International Sympoisum on the Immunocompromised Host. Davos (Switzerland), 19–24 June 1994, Abstract no. 39.

    Google Scholar 

  15. Klastersky J, Zinner SH, Calandra T, et al. 1988. Empiric antimicrobial therapy for febrile, granulocytopenic cancer patients: Lesson from 4 EORTC trials. Eur J Cancer Clin Oncol 24(Suppl 1): S35-S45.

    PubMed  Google Scholar 

  16. Viscoli C, Castagnola E, Rogers D. 1991. Infections in the compromised child. Clin Haematol 4:511–543.

    CAS  Google Scholar 

  17. Schimpff SC. 1990. Infections in the compromised host. In: Mandell GL, Douglas RG Jr, Bennett JE, eds Principles and Practice of Infectious Diseases. New York: Churchill Livingstone, pp 2258–2265.

    Google Scholar 

  18. Pizzo PA, Rubin M. 1993. Infectious complications in children with hematologic disorder. In: Nathan DG, Oski FA, eds Hematology of Infant and Childhood. Philadelphia: WB Saunders, pp 1730–1753.

    Google Scholar 

  19. Axelrod PI, Lorber B, Vonderheid EC. 1992. Infections complicating mycosis fungoides and Sezary syndrome. JAMA 267:1354–1358.

    PubMed  CAS  Google Scholar 

  20. Meyers JD. 1990. Fungal infections in bone marrow transplant patients. Semin Oncol 17:10–13.

    PubMed  CAS  Google Scholar 

  21. Bodey GP, Buckley M, Sathe YS, et al. 1966. Quantitative relationship between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64:328–340.

    PubMed  CAS  Google Scholar 

  22. Viscoli C, Bruzzi P, Castagnola E, et al. 1994. Factors predicting bacteremia in febrile granulocytopenic cancer patients. Eur J Cancer 30A:430–437.

    PubMed  CAS  Google Scholar 

  23. Chanock S. 1993. Evolving risk factors for infectious complications of cancer therapy. Hematol Oncol Clin North Am 7:771–793.

    PubMed  CAS  Google Scholar 

  24. Khardori N. 1989. Host-parasite interaction in fungal infections. Eur J Clin Microbiol Infect Dis 8:331–351.

    PubMed  CAS  Google Scholar 

  25. Guiot HFL, Fibbe E, Van’t Wout W. 1994. Risk factors for fungal infections in patients with malignant hematologic disorders: Implications for empirical therapy and prophylaxis. Clin Infect Dis 18:525–532.

    PubMed  CAS  Google Scholar 

  26. EORTC International Antimicrobial Therapy Cooperative Group. 1991. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. J Infect Dis 163:951–958.

    Google Scholar 

  27. Van Der Meer JWM. 1988. Defects in host-defense mechanisms. In: Rubin RH, Young LS, eds Clinical Approach to Infection in the Compromised Patient. New York: Plenum, pp 41–73.

    Google Scholar 

  28. Shearer WT, Anderson DC. 1989. The secondary immunodeficiencies. In: Stiehm ER, ed Immunologic Disorders in Infant and Children. Philadelphia: WB Saunders, pp 400–438.

    Google Scholar 

  29. Atkinson K. 1990. Reconstruction of the haemopoietic and immune systems after bone marrow transplantation. Bone Marrow Transpl 5:209–226.

    CAS  Google Scholar 

  30. Sheridan JF, Tutschka PJ, Sedmak DD, et al. 1990. Immunoglobulin G subclass deficiency and pneumococcal infection after allogeneic bone marrow transplantation. Blood 75:1583–1586.

    PubMed  CAS  Google Scholar 

  31. Kahls P, Kier P, Lechner K. 1990. Functional asplenia after bone marrow transplantation. Ann Intern Med 114:805–806.

    Google Scholar 

  32. Weeks JC, Tierney MR, Weinstein MC. 1991. Cost-effectiveness of prophylactic intravenous immunoglobulin in chronic lymphocytic leukemia. N Engl J Med 325:81–86.

    PubMed  CAS  Google Scholar 

  33. Wolff SN, Fay JW, Herzig RH, et al. 1993. High dose weekly intravenous immunoglobulins to prevent infections in patients undergoing autologous bone marrow transplantation or severe myelosuppressive therapy. Ann Intern Med 118:936–942.

    Google Scholar 

  34. Young RC, Corder MP, Haynes HA, et al. 1972. Delayed hypersensitivity in Hodgkin’s disease. Am J Med 56:63–72.

    Google Scholar 

  35. De Marie S. 1993. Diseases and drug-related interventions affecting host defence. Eur J Clin Microbiol Infect Dis 12(Suppl 1): S36-S41.

    PubMed  Google Scholar 

  36. Kim JH, Perfect JR. 1989. Infection and cyclosporine. Rev Infect Dis 11:677–690.

    PubMed  CAS  Google Scholar 

  37. Cupps TR, Fauci AS. 1982. Corticosteroid-mediated immunoregulation in man. Immunol Rev 65:133–155.

    PubMed  CAS  Google Scholar 

  38. Masur H, Ognibene FP, Yarchoan R, et al. 1989. CD4 counts as predictors of opportunistic pneumonias in human immunodeficiency virus (HIV) infection. Ann Intern Med 111:223–231.

    PubMed  CAS  Google Scholar 

  39. Leiboboviz E, Rigaud M, Pollack K, et al. 1990. Pneumocystis carinii pneumonia in infants infected with human immunodeficiency virus with more than 450 CD4 T lymphocytes per cubic millimeter. N Engl J Med 323:531–533.

    Google Scholar 

  40. Mackall CL, Fleisher TA, Brown MR, et al. 1994. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood 84:2221–2228.

    PubMed  CAS  Google Scholar 

  41. Hughes WT, Mcnabb PC, Makres TD, et al. 1974. Efficacy of trimethoprim and sulfamethoxazole in the prevention and treatment of Pneumocystis carinii pneumonitis. Antimicrob Agents Chemother 5:289–293.

    PubMed  CAS  Google Scholar 

  42. Sepkowitz KA, Brown AE, Telzak EE, et al. 1992. Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. JAMA 267:832–837.

    PubMed  CAS  Google Scholar 

  43. Sepkowitz KA. 1993. Pneumocystis carinii pneumonia in patients without AIDS. Clin Infect Dis 17(Suppl 2):S416–S422.

    PubMed  Google Scholar 

  44. Dallorso S, Castagnola E, Garaventa A, et al. 1994. Early onset of Pneumocystis carinii pneumonia in a patient receiving bone marrow transplantation from a matched unrelated donor. Bone Marrow Transpl 13:106–107.

    CAS  Google Scholar 

  45. Castagnola E, Dini G, Lanino E, et al. 1995. Low C04 Lymphocyte count in a patient with P. Carinii Pneumonia after autologous bone marrow transplantation. Bone Marrow Transplant. 15:977–978.

    PubMed  CAS  Google Scholar 

  46. Mackall CL, Fleisher T, Brown MR, et al. 1995. AGE, Thymopoiesis, and CD4+ T-Lymphocyte regeneration after intensive chemotherapy. N ENGL J Med 332:143–149.

    PubMed  CAS  Google Scholar 

  47. Janmohamed R, Morton JE, Milligan DW, et al. 1990. Herpes simplex in oral ulcers in neutropenic patients. Br J Cancer 61:469–470.

    PubMed  CAS  Google Scholar 

  48. Carrega G, Castagnola E, Canessa A, et al. 1994. Herpes simplex virus and oral mucositis in children with cancer. Support Care Cancer, 2:266–269.

    PubMed  CAS  Google Scholar 

  49. Awada A, Van Der Auwera P, Meunier F, et al. 1992. Streptococcal and enterococcal bacteremia in patients with cancer. Clin Infect Dis 15:33–48.

    PubMed  CAS  Google Scholar 

  50. Cafiero F, Gipponi M, Moresco L, et al. 1989. Selection of preoperative haematobiological parameters for the identification of patients ‘at risk of infection’ undergoing surgery for gastrointestinal cancer. Eur J Surg Oncol 15:247–252.

    PubMed  CAS  Google Scholar 

  51. Wade DS, Nava HR, Douglass HO Jr. 1992. Neutropenic enterocolitis. Clin Diagn Treatment. Cancer 69:17–23.

    PubMed  CAS  Google Scholar 

  52. Sparks FC. 1976. Hazards and complications of BCG immunotherapy. Med Clin North Am 60:499–509.

    PubMed  CAS  Google Scholar 

  53. Ritch PS, Mccredie KB, Gutterman JU, et al. 1978. Disseminated BCG disease associated with immunotherapy by scarification in acute leukemia. Cancer 42:167–170.

    PubMed  CAS  Google Scholar 

  54. Snydman DR, Sullivan D, Gill M, et al. 1990. Nosocomial sepsis associated with interleukin-2. Ann Intern Med 112:102–107.

    PubMed  CAS  Google Scholar 

  55. Pokaj BA, Topalian SL, Steinberg SM, et al. 1993. Infectious complications associated with interleukin-2 administration: A retrospective review of 935 treatment courses. J Clin Oncol 11:136–147.

    Google Scholar 

  56. Klemper MS, Noring R, Mier JW, et al. 1990. An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapy. N Engl J Med 322:959–965.

    Google Scholar 

  57. Donfrancesco A, Deb G, Dominici C, et al. 1990. Effects of a single course of deferoxamine in neuroblastoma patients. Cancer Res 50:4929–4930.

    PubMed  CAS  Google Scholar 

  58. Bentur Y, Mcguigan M, Koren G. 1991. Deferoxamine (desferrioxamine). New toxicities for an old drug. Drug Safety 6:37–46.

    PubMed  CAS  Google Scholar 

  59. Castagnola E, Garaventa A, Conte M, et al. 1993. Survival after fungemia due to Fusarium moniliforme in a child with neuroblastoma. Eur J Clin Microbiol Infect Dis 12:308–309.

    PubMed  CAS  Google Scholar 

  60. Elting LS, Bodey GP, Keefe BH. 1992. Septicemia and shock syndrome due to Viridans streptococci: A case control study of predisposing factors. Clin Infect Dis 14:1201–1207.

    PubMed  CAS  Google Scholar 

  61. Kensh GT. 1984. Nutrition and infection. In: Remington JS, Swartz MN, eds Current Clinical Topics in Infectious Diseases. New York: McGraw-Hill, pp 106–123.

    Google Scholar 

  62. Steffen EK, Berg D, Deitch EA. 1988. Comparison of translocation rates of various indigenous bacteria from gastrointestinal tract to mesenteric lymph nodes. J Infect Dis 157:1032–1038.

    PubMed  CAS  Google Scholar 

  63. Crislip MA, Edwards JE. 1989. Candidiasis. Infect Dis Clin North Am 3:103–133.

    CAS  Google Scholar 

  64. Powell DA, August J, Snedden S, et al. 1984. Broviac catheter-related Malassezia furfur sepsis in five infants receiving intravenous fat emulsion. J Pediatr 105:987–990.

    PubMed  CAS  Google Scholar 

  65. Freeman J, Goldman DA, Smith NE, et al. 1990. Association of intravenous lipid emulsion and coagulase negative staphylococcal bacteremia in neonatal intensive care unit. N Engl J Med 323:301–308.

    PubMed  CAS  Google Scholar 

  66. Solomon SL, Khabbaz RF, Parker RH, et al. 1984. An outbreak of Candida Parapsilosis bloodstream infections in patients receiving parenteral nutrition. J Infect Dis 149:98–102.

    PubMed  CAS  Google Scholar 

  67. Maki DG. 1986. Infections due to infusion therapy. In: Bennet JV, Brachman PS, eds Hospital Infections. Boston: Little Brown, pp 561–580.

    Google Scholar 

  68. Viscoli C, Garaventa A, Boni L, et al. 1988. Role of broviac catheters in infections in children with cancer. Pediatr Infect Dis J 7:556–560.

    PubMed  CAS  Google Scholar 

  69. Goldmann DA, Pier GB. 1993. Pathogenesis of infections related to intravascular catheterization. Clin Microbiol Rev 6:176–192.

    PubMed  CAS  Google Scholar 

  70. Maki DG. 1989. Pathogenesis, prevention, and management of infections due to intravascular devices used for infusion therapy. In: Bisno AL, Waldvogel FA, eds Infections associated with indwelling medical devices. Washington, DC: American Society for Microbiology, pp 161–177.

    Google Scholar 

  71. Clarke DE, Raffln TA. 1990. Infectious complications of indwelling long-term central venous catheters. Chest 97:966–972.

    PubMed  CAS  Google Scholar 

  72. Castagnola E, Garaventa A, Viscoli C, et al. 1994. Changing pattern of catheter related infections in children with cancer. J Hosp Infect, 29:129–133.

    Google Scholar 

  73. Pegues DA, Carson LA, Anderson RL, et al. 1993. Outbreak of Pseudomonas cepacia bacteremia in oncology patients. Clin Infect Dis 16:407–411.

    PubMed  CAS  Google Scholar 

  74. Groeger JS, Lucas AB, Thaler HT, et al. 1993. Infectious morbidity associated with long-term use of venous access devices in patients with cancer. Ann Intern Med 119:1168–1174.

    PubMed  CAS  Google Scholar 

  75. Castagnola E, Carrega G, Garauenta A. 1994. Catheter-related bacteremias in patients with cancer. ANN Intern Med 121:72–73.

    PubMed  CAS  Google Scholar 

  76. Allen JR. 1987. Transmission of human immunodeficiency virus (HIV) by blood and blood components. In: Moore SB, Alter HJ, eds Transfusion transmitted viral diseases. Arlington, VA: American Association of Blood Banks, pp 37–48.

    Google Scholar 

  77. Bowden RA, Meyers JD. 1990. Transfusion-associated cytomegalovirus infection. In: Dutcher JP, ed Modern Transfusion Therapy, Vol 2. Boca Raton, FL: CRC Press, pp 269–282.

    Google Scholar 

  78. Soulier JP. 1984. Diseases transmissible by blood transfusion. Vox Sang 47:1–6.

    PubMed  CAS  Google Scholar 

  79. Alter HJ, Purcell RH, Shih JW, et al. 1989. Detection of Antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 321:1494–1500.

    PubMed  CAS  Google Scholar 

  80. Gole E, Nankervis GA. 1982. Cytomegalovirus. In: Evans AS, ed Viral Infections of Humans: Epidemiology and Control. New York: Plenum Publishing, pp 167–186.

    Google Scholar 

  81. Sayers MH, Anderson KC, Goodnough LT, et al. 1992. Reducing the risk for transfusion-trasmitted cytomegalovirus infection. Ann Intern Med 116:55–62.

    PubMed  CAS  Google Scholar 

  82. Barbara JAJ, Contreras M. 1990. Infectious complications of blood transfusion: Bacteria and parasites. Br Med J 300:386–389.

    CAS  Google Scholar 

  83. Yomtovian R, Lazarus HM, Goodnough LT, et al. 1993. A prospective microbiologic surveillance program to detect and prevent the transfusion of bacterially contaminated platelets. Transfusion 33:902–909.

    PubMed  CAS  Google Scholar 

  84. Mayer KH, Opal SM. 1989. Unusual nosocomial pathogens. Infect Dis Clin North Am 3:883–899.

    PubMed  CAS  Google Scholar 

  85. Grant IH, Gold JWM, Wittner M, et al. 1989. Transfusion-associated acute Chagas disease acquired in the United States. Ann Intern Med 111:849–851.

    PubMed  CAS  Google Scholar 

  86. Nickerson P, Orr P, Schroeder MI, et al. 1989. Transfusion-associated Trypanosoma cruzi infection in a non-endemic area. Ann Intern Med 111:851–853.

    PubMed  CAS  Google Scholar 

  87. Guerrero IC, Weniger BG, Schultz MG. 1983. Transfusion malaria in the United States, 1972–1981. Ann Intern Med 99:221–226.

    PubMed  CAS  Google Scholar 

  88. Gottesdiener KM. 1989. Transplanted infections: Donor-to-host transmission with the allograft. Ann Intern Med 110:1001–1016.

    PubMed  CAS  Google Scholar 

  89. Centers for Disease Control and Prevention. 1994. Guidelines for Preventing Transmission of Human Immunodeficiency Virus Through Transplantation of Human Tissues and Organs. MMWR 43:[No.RR-8):l–17.

    Google Scholar 

  90. Kelly CP, Pothoulakis C, Lamont JT. 1994. Clostridium difficile colitis. N Engl J Med 330:257–262.

    PubMed  CAS  Google Scholar 

  91. Anand A, Glatt AE. 1993. Clostridium difficile infection associated with antineoplastic chemotherapy: A review. Clin Infect Dis 17:109–113.

    PubMed  CAS  Google Scholar 

  92. The GIMEMA Infection Program. 1991. Prevention of bacterial infection in neutropenic patients with hematologic malignancies: A randomised multicenter trial comparing norfloxacin with ciprofloxacin. Ann Intern Med 115:7–12.

    Google Scholar 

  93. Shaes DM, Binezewski B, Rice BL. 1993. Emerging antimicrobial resistance and the immunocompromised host. Clin Infect Dis 17(Suppl 2):S527-S536.

    Google Scholar 

  94. Cometta A, Calandra T, Bille J, et al. 1994. Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. N Engl J Med 330:1240–1241.

    PubMed  CAS  Google Scholar 

  95. Walsh TJ, Hiemenz J, Pizzo PA. 1994. Editorial response: Evolving risk factors for invasive fungal infections—All neutropenic patients are not the same. Clin Infect Dis 18:793–798.

    PubMed  CAS  Google Scholar 

  96. Goodman JL, Winston DJ, Greenfield RA, et al. 1992. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 326:845–851.

    PubMed  CAS  Google Scholar 

  97. Wingard JR, Merz WG, Rinaldi MG, et al. 1991. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 325:1274–1277.

    PubMed  CAS  Google Scholar 

  98. Mcquillen DP, Zingman BS, Meunier F, et al. 1992 Invasive infections due to Candida krusei: Report of ten cases of fungemia that include three cases of endophthalmitis. Clin Infect Dis 14:472–478.

    PubMed  CAS  Google Scholar 

  99. Boken DJ, Swindells S, Rinaldi MG. 1993 fluconazole-resistant Candida albicans. Clin Infect Dis 17:1018–1021.

    PubMed  CAS  Google Scholar 

  100. Wingard JR, Merz WG, Rinaldi MG, Miller CB, Karp JE, Sarai R. 1993 Association of Torulopsis glabrata infection with fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemother 37:1847–1849.

    PubMed  CAS  Google Scholar 

  101. Fan-Havard P, Capano D, Smith SM, et al. 1991. Development of resistence in Candida isolates from patients receiving prolonged antifungal therapy. Antimicrob Agents Chemother 35:2302–2305.

    PubMed  CAS  Google Scholar 

  102. Como JA, Dismukes WE. 1994. Oral azole durgs as systemic antifungal therapy. N Engl J Med 330:263–272.

    PubMed  CAS  Google Scholar 

  103. Chatis PA, Crumpacker CS. 1992. Resistance of herpesviruses to antiviral drugs. Antimicrob Agents Chemother 36:1589–1595.

    PubMed  CAS  Google Scholar 

  104. Goodrich JM, Bowden RA, Fisher L, et al. 1993. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 118:173–178.

    PubMed  CAS  Google Scholar 

  105. Kunin CM. 1993 resistance to antimicrobial drugs—A worldwide calamity. Ann Intern Med 118:557–561.

    PubMed  CAS  Google Scholar 

  106. Cohen ML. 1992. Epidemiology of drug resistance: implications for a post-antimicrobial era. Science 257:1050–1055.

    PubMed  CAS  Google Scholar 

  107. Neu HC. 1992. The crisis of antibiotic resistance. Science 257:1064–1073.

    PubMed  CAS  Google Scholar 

  108. Feld R. 1989. The compromised host. Eur J Cancer Clin Oncol 25(Suppl 2):S1-S8.

    PubMed  Google Scholar 

  109. Skogberg K, Ruutu P, Tukiainen P, et al. 1993. Effect of immunosuppressive therapy on the clinical presentation and outcome of tuberculosis. Clin Infect Dis 17:1012–1017.

    PubMed  CAS  Google Scholar 

  110. Israelski DM, Remington JS. 1993. Toxoplasomisis in patients with cancer. Clin Infect Dis 17(Suppl 2):S423-S435.

    PubMed  Google Scholar 

  111. Winston DJ, Ho WG, Champlin RE. 1990. Cytomegalovirus infections after allogeneic bone marrow transplantation. Rev Infect Dis 12(Suppl 7):S776-S804.

    PubMed  Google Scholar 

  112. Muller SA, Hermann EC Jr, Winkelmann RK. 1972. Herpes simplex infections in hematologic malignancies. Am J Med 52:102–114.

    PubMed  CAS  Google Scholar 

  113. Straus SE, Moderator. 1993. Epsetin Barr virus infections: Biology, pathogenesis and management. Ann Intern Med 118:45–58.

    PubMed  CAS  Google Scholar 

  114. Flowers MA, Heathcote J, Wanless IR, et al. 1990. Fulminant hepatitis as a consequnece of reactivation of hepatitis B virus infection after discontinuation of low-dose methotrexate therapy. Ann Intern Med 112:381–382.

    PubMed  CAS  Google Scholar 

  115. Lok ASF, Liang RHS, Chung H. 1992. Recovery from chronic Hepatitis B. Ann Intern Med 116:967.

    Google Scholar 

  116. Kaplan MH. 1993. Human retroviruses and neoplastic diseases. Clin Infect Dis 17(Suppl 2):S400–S406.

    PubMed  Google Scholar 

  117. Asano Y, Yoshikawa T, Suga S, et al. 1991. Reactivation of herpes virus type 6 in children receiving bone marrow transplants for leukemia. N Engl J Med 324:634–635.

    PubMed  CAS  Google Scholar 

  118. Cone RW, Hackman RC, Huang MW, et al. 1993. Human herpes virus 6 in lung tissue from patients with pneumonitis after bone marrow transplantation. N Engl J Med 329:156–161.

    PubMed  CAS  Google Scholar 

  119. Waldmann TA. 1988. Immunodeficiency diseases: Primary and acquired. In: Samter M, Talmage DW, Frank MM, Austen KF, Claman HN, eds Immunological diseases. Boston: Little Bown, pp 441–465.

    Google Scholar 

  120. Anonimous. 1987. Normal microbial flora of the human body. In: Jawetz E, Melnick JL, Adelberg EA, eds Review of Medical Microbiology. East Norwalk, CT: Appleton and Lange, pp 314–317.

    Google Scholar 

  121. Isenber HD, D’Amato RF. 1991. Indigenous and pathologic microorganisms of humans. In: Balows A, Hausler WJ Jr, Herrmann KL, Isenberg HD, Shadomy HJ, eds Manual of Clinical Microbiology. Washington DC: American Society For Microbiology, pp 2–14.

    Google Scholar 

  122. Roth RR, James W. 1989. Microbiology of the skin: Resident flora, ecology, infection. J Am Acad Dermatol 20:367–390.

    PubMed  CAS  Google Scholar 

  123. Schimpff SC, Young V, Greene E, et al. 1972. Origin of infection in acute non-lymphocytic leukemia: Significance of hospital acquisition of potential pathogens. Ann Intern Med 77:707–715.

    PubMed  CAS  Google Scholar 

  124. Tuazon CU. 1984. Skin and skin infections in the patient at risk: Carrier state of Staphylococcus aureus. Am J Med 76:166–171.

    PubMed  CAS  Google Scholar 

  125. Bauer TM, Ofner E, Just HM, et al. 1990. An epidemiological study assessing the relative importance of airborne and direct contact transmission of microorganisms in a medical intensive care unit. J Hosp Infect 15:301–309.

    PubMed  CAS  Google Scholar 

  126. Wenzel RP, Thompson RL, Landry SM, et al. 1983. Hospital-acquired infections in intensive care unit patients: An overview with emphasis on epidemics. Infect Control 4:371–375.

    PubMed  CAS  Google Scholar 

  127. Brown AE. 1990. Overview of fungal infections in cancer patients. Semin Oncol 17(Suppl 6):2–5.

    CAS  Google Scholar 

  128. Drutz DJ. 1988. Fungal infections. In: Samter M, Talmage DW, Frank MM, Austen KF, Claman HN, eds Immunological Diseases. Boston: Little Bown, pp 863–898.

    Google Scholar 

  129. Bennett JE. 1985. Aspergillus species. In: Mandell GL, Douglas RG Jr, Bennett JE, eds Principles and Parctice of Infectious Diseases. New York: John Wiley, pp 1447–1451.

    Google Scholar 

  130. Pizzo PA. 1993. Fever in patients with neutropenia. N Engl J Med 329:1280.

    Google Scholar 

  131. Dondero TJ, Rendtorff RC, Mallison GF, et al. 1980. An outbreak of Legionnaries’ disease associated with a contaminated air-conditioning cooling tower. N Engl J Med 302:365–370.

    PubMed  Google Scholar 

  132. Helms CM, Massanari RM, Zeitler R, et al. 1983. Legionnaries’ disease associated with a hospital water systm: A cluster of 24 nosocomial cases. Ann Intern Med 99:172–178.

    PubMed  CAS  Google Scholar 

  133. Cordes LG, Wiesenthal AM, Gorman GW, et al. 1981. Isolation of Legionella pneumophila from hospital shower heads. Ann Intern Med 94:195–195.

    PubMed  CAS  Google Scholar 

  134. Wade JC, Schimpff SC. 1988. Epidemiology and prevention of infection in the compromised host. In: Rubin RH, Young LS, eds Clinical Approach to Infection in the Compromised Patient. New York: Plenum, pp 5–40.

    Google Scholar 

  135. Anonymous. 1987. The microbiology of special environments. In: Jawetz E, Melnick JL, Adelberg EA, eds Review of Medical Microbiology. East Norwalk, CT: Appleton and Lange, pp 110–120.

    Google Scholar 

  136. Litchfield JH. 1976. Food microbiology. In: Miller BM, Litsky W, eds Industrial Microbiology. New York: McGraw-Hill, pp 257–308.

    Google Scholar 

  137. Mooney BR, Reeves SA, Larson E. 1993. Infection control and bone marrow transplantation. Am J infect Control 21:131–138.

    PubMed  CAS  Google Scholar 

  138. Rubenstein EB, Rolston K, Benjamin RS, et al. 1993. Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer 71:3640–3646.

    PubMed  CAS  Google Scholar 

  139. Griffin TC, Buchanan GR. 1992. Hematologic predictors of bone marrow recovery in neutropeic patients hospitalized for fever: Implications for discontinuation of antibiotics and early discharge from the hospital. J Pediatr 121:28–33.

    PubMed  CAS  Google Scholar 

  140. Mullen CA, Buchanan GR. 1990. Early hospital discharge of children with cancer treated for fever and neutropenia: Identification and management of the low-risk patient. J Clin Oncol 8:1998–2004.

    PubMed  CAS  Google Scholar 

  141. Wiernikowski JT, Rothney M, Dawson S, Andrew M. 1991. Evaluation of home intravenous antibiotic program in pediatric oncology. Am J Pediatr Hematol Oncol 13:144–147.

    PubMed  CAS  Google Scholar 

  142. Talcott JA, Finberg R, Mayer RJ, et al. 1988. The medical course of cancer patients with fever and neutropania. Clinical identification of a low risk subgroup at presentation. Arch Intern Med 148:2561–2568.

    PubMed  CAS  Google Scholar 

  143. Talcott JA, Siegel RD, Finberg R, et al. 1992. Risk assessment in cancer patients with fever and neutropenia: A prospective, two-center validation of a prediction rule. J Clin Oncol 10:316–322.

    PubMed  CAS  Google Scholar 

  144. De Jongh CA, Wade JC, Schimpff SC, et al. 182. Empiric antibiotic therapy for suspected infections in granulocytopenic cancer patients. A comparison between the combination of moxalactam plus amikacin and ticarcillin plus amikacin. Am J Med 73:89–96.

    Google Scholar 

  145. Viscoli C, Moroni C, Boni L, et al. 1991. Ceftazidime plus amikacin versus ceftazidime plus vancomycin as empiric therapy in febrile neutropenic children with cancer. Rev Infect Dis 13:397–404.

    PubMed  CAS  Google Scholar 

  146. EORTC—International Antimicrobial Therapy Project Group. 1988. Three antibiotic regimens in the treatment of infections in febrile granulocytopenic patients with cancer. J Infect Dis 137:14–29.

    Google Scholar 

  147. EORTC—International Antimicrobial Therapy Project Group. 1983. Combination of amikacin and carbenicillin with or without cefazolin as empirical treatment of febrile neutropenic patients. J Clin Oncol 1:597–603.

    Google Scholar 

  148. EORTC—International Antimicrobial Therapy Project Group. 1986. Prospective randomized comparison of three antibiotic regimens for empirical bacteremic infections in febrile granulocytopenic patients. Antimicrob Agents Chemother 29:263–270.

    Google Scholar 

  149. EORTC—International Antimicrobial Therapy Cooperative Group. 1987. Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients. N Engl J Med 317:1692–1698.

    Google Scholar 

  150. EORTC—International Antimicrobial Therapy Cooperative Group. 1990. Gram-positive bacteremia in granulocytopenic cancer patients. Eur J Cancer 26:569–574.

    Google Scholar 

  151. Pizzo PA. 1981. Infectious complications in the child with cancer. I Pathophysiology of the compromised host and the initial evaluation and management of the febrile cancer patient. J Pediatr 98:341–354.

    PubMed  CAS  Google Scholar 

  152. Love LJ, Schimpff SC, Schiffer CA. 1980. Improved prognosis for granulocytopenic patients with gram-negative bacteremia. AM J Med 68:643–648.

    PubMed  CAS  Google Scholar 

  153. Karp JF, Merz WG, Hendricksen C, et al. 1987. Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia: A randomized, double-blind, placebo-controlled trial. Ann Intern Med 106:1–7.

    PubMed  CAS  Google Scholar 

  154. Metz CE. 1978. Basic principles of ROC analysis. Semin Nucl Med 8:283–298.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Claudio Viscoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elio Castagnola
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Service de Medecine Interne et Laboratoire d’Inverstigation, Clinique, H.J. Tagnon, Institut Jules Bordet, Centre des Tumeurs de L’Universite, Libre de Bruxelles, Belgium

    Jean Klastersky

Rights and permissions

Reprints and permissions

Copyright information

© 1995 Kluwer Academic Publishers

About this chapter

Cite this chapter

Viscoli, C., Castagnola, E. (1995). Factors predisposing cancer patients to infection. In: Klastersky, J. (eds) Infectious Complications of Cancer. Cancer Treatment and Research, vol 79. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1239-0_1

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-1239-0_1

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4612-8527-4

  • Online ISBN: 978-1-4613-1239-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation